Brokers Set Expectations for Galecto FY2029 Earnings

Galecto, Inc. (NASDAQ:GLTO) – Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Galecto in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($4.14) per share for the year. The consensus estimate for Galecto’s current full-year earnings is ($15.59) per share.

Separately, Oppenheimer upped their price objective on Galecto from $9.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th.

Galecto Trading Down 8.1 %

GLTO stock opened at $4.55 on Friday. The stock has a market cap of $5.99 million, a PE ratio of -0.24 and a beta of 1.17. Galecto has a 12 month low of $4.40 and a 12 month high of $23.50. The company has a 50-day moving average price of $5.18 and a 200 day moving average price of $8.42.

About Galecto

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.